An interventional study of Dry needling in Low Back Pain, sponsored by Texas Woman's University. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Texas Woman's University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Low Back Pain by Texas Woman's University — none open to participants now, none under way, none of them phase 3. Low Back Pain · Texas Woman's University.
Among the 12 studies in Low Back Pain by Texas Woman's University, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 10 with no phase, and was the 12th registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →None of the 12 studies in Low Back Pain by Texas Woman's University is open now. The open studies under Low Back Pain, anywhere →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2022.
This study's enrollment of 50 is below the median of 60 across 2,369 interventional studies indexed under Low Back Pain.
Median enrollment 40 across the 10 interventional studies, 36 across the 2 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
Texas Woman's University is the lead sponsor of 86 studies on the registry; 6 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Low Back Pain by Texas Woman's University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators plan to use a pre-test post-test research design to investigate whether dry needling (DN) has an effect on cortical excitability in patients with chronic low back pain (CLBP), specifically in patients who have developed central sensitization (CS). Therefore, the primary purpose of this study is to examine the immediate effects of a single session of DN on cortical excitability and neurosensory responses in patients CLBP. There are two specific aims: 1) to examine whether a single session of DN will change cortical excitability corresponding to the lumbar multifidus (LM) muscle, and 2) to examine whether a single session of DN will change neurosensory responses to the stimuli applied to the LM muscles.
The investigators also are interested in exploring whether DN has a differential effect on cortical excitability in patients with CLBP who have developed CS vs. those who have not developed CS. Therefore, the secondary purpose of the study is to compare the immediate effects of a single session of DN on cortical excitability between patients with CLBP who have developed central sensitization (CS) and those who do not have CS. The specific aim is to compare cortical excitability corresponding to the LM in participants with and without CS after a single session of DN.
Research Design:
This study will be pre-test post-test trial, in which all eligible participants will receive a single session of dry needling (DN). All outcome measures will be collected before and immediately after a single session of DN.
Procedure:
Eligible participants will be asked to complete an intake form, asking them about their demographic data, including age, gender, height, weight, occupation, past medical history, and questions related to their low back pain (onset, injury mechanism if any, location, duration, type, and nature). Once the participant's eligibility is confirmed, each participant will complete the Central Sensitization Inventory (CSI) questionnaire to assign each participant either in the CS group or non-CS group using the 40 cutoff score of the CSI.
Clinical Assessments:
Each participant will complete 3 self-reported questionnaires before cortical excitability assessment, including pain intensity determined using the Numeric Pain Rating Scale (NPRS), disability determined using the Modified Oswestry Low Back Pain Disability Questionnaire (modified ODI), and quality of life determined by the Patient-Reported Outcomes Measurement Information System® -short form (PROMIS-29). These questionnaires will be used to describe the characteristics of the participants in this study.
Cortical Excitability Assessment:
Three cortical excitability parameters will be collected: amplitudes of motor evoked potentials (MEPs), intracortical facilitation (ICF) values, and short-interval cortical inhibition (SICI) values. Participants will lie in a prone position for the electromyographic (EMG) setup. EMG activity will be collected from the painful side of the L4-5 area. Following the recommendations of the Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles (SENIAM) project, the electrode for the LM will be placed at the L4-5 level, approximately 2-3 cm from the midline, and will be aligned with a line from the posterior superior iliac spine (PSIS) to the interspace between the L1 and L2 spinous process.
To obtain MEPs of the LM muscle, the M1 (primary motor cortex) will be stimulated while the participant performs a submaximal voluntary contraction. First, the maximum voluntary isometric contractions (MVIC) of the LM will be determined. During the MVIC testing, each participant will perform the maximum upper extremity and trunk lift with the elbows flexed to approximately 90° and shoulders abducted to approximately 120°, and maintain the lift for 3 seconds while resisting against a load applied at the opposite elbow of the painful side by the testing investigator. Two trials each will be performed and the highest root mean square (RMS) of EMG amplitude will be identified. During the cortical excitability assessment, a target line representing \~ 20% of highest RMS value during MVIC will be placed on the real-time EMG monitor while the participant will be asked to maintain the target LM activation by slightly leaning forward and to maintain lumbar lordosis in a seated position.
Following the MVIC testing, each participant will be seated on a chair for cortical excitability assessment. A "hot spot" will be determined while the participant maintains a 20% submaximal contraction of the LM (i.e., slightly leaning forward and maintain lumbar lordosis). A hot spot is defined as the site at which the largest MEP amplitude is obtained at the lowest TMS stimulation intensity or output (0-100%). The double-cone coil will be positioned over the M1 area opposite to the participant's most painful side. The intensity of TMS stimulation from one TMS stimulator will begin at 35% of stimulator output and then will be increased gradually to yield a MEP from the LM until a 'hot spot' is observed. Next, the active motor threshold (AMT) will be determined. AMT is defined as the stimulation intensity which yields a peak-to-peak amplitude of MEP larger than 200 μV in 5 out of 10 consecutive trials. Once the AMT is determined, the stimulation intensity will be set at 130% of AMT and 10 stimulations will be delivered to the hot spot. The 10 supra-threshold MEP amplitudes (uV) recorded from the LM will be averaged and the average will be used for statistical analysis.
For the ICF and SICI testing, two stimuli, one conditioning stimulus and one test stimulus, will be generated from two TMS stimulators connected by a coil (BiStim Module, Magstim Co., UK). In ICF, a subthreshold conditioning (second) TMS at the 90% AMT will be delivered to the hot spot 15 ms after a test (first) TMS at the 100% AMT. In SICI, a subthreshold conditioning TMS at 70% AMT will be delivered 2 ms before a test TMS at a supra-threshold test TMS at 120% AMT. For both ICF and SICI, the amplitude of the conditioned MEP will be expressed relative to the amplitude of the corresponding test MEP. Ten trials will be performed for each of the ICF and SICI tests, and the average of the 10 trials will be used for statistical analysis.
Quantitative Sensory Tests (QSTs):
The two QSTs, pressure pain thresholds (PPTs) and conditioned pain modulation (CPM) tests, will be administered after the cortical excitability assessments both before and after the DN intervention. During the PPT, participants will be given a response button to stop testing on their own, and will be instructed to stop the test as soon as the pressure becomes uncomfortable or painful, and not to allow an uncomfortable or painful sensation to continue. Four trials will be tested on the most tender point around L4-5, but the first trial will be counted as a practice trial. The average of the last three trials will be used for statistical analysis.
For the CPM test, a thermode will be applied to the most tender point of the low back and then heat temperature will increase at 1°/sec to the point until the participant perceives the heat stimuli painful at 6/10 on the numeric pain rating scale (NPRS). Two thermodes which generate heat stimuli at the temperature that the participant rates 6/10 on the NPRS will be used for the CPM testing, one applied to the most tender point of the low back (test stimulus), and the other on the contralateral side of forearm (conditioning stimulus). The NPRS scores will be collected under the two conditions: test stimuli alone and combined test stimuli and conditioning stimuli. The test stimuli will be applied first for 10 seconds and then the conditioning stimuli for 25 seconds, so that the second application of the testing stimuli (for 10 seconds) would occur after 15 seconds of conditioning stimuli.
Dry Needling Intervention:
Two lengths of sterile, disposable, 0.30 mm x 60 mm solid filament needles (Seirin Corp., Shizuoka, Japan) and 0.30 mm x 100 mm solid filament needles (Shanghai Kangnian Medical Device Co., Ltd., Shanghai, China) will be used in the study. The length of the needle for each participant will be selected based on the size of the participant. Two needles will be inserted on or near the most tender point of the low back. Two additional needles will be inserted on the opposite side at the level of the most tender point regardless of unilateral or bilateral LBP. After piercing the skin, the needle will be directed toward the spinous process in a slight inferior-medial angle (approximately 20-30°). Once the needle is inserted, the treating investigator will use ultrasound (US) scanner to visualize the needle placement and to confirm that needle has reached the deeper layer of the LM. Once the needle placement is confirmed, it will be pulled slightly in and out within the muscle and redirected in small angles for 10 seconds after insertion. The needles will stay (in situ) in the LM for approximately 10 minutes after the insertion and then will be withdrawn.
Descriptive statistics will be calculated for participant characteristics as well as baseline outcome measures (amplitudes of MEPs, ICF values, SICI values, PPTs, and CPM scores) of all participants. Independent t-tests will be used to compare the ratio data of participant characteristics, self-reported questionnaires, and baseline outcome measures between the two groups. Chi-square statistics will be used to analyze categorical data of participant characteristics (e.g., sex, side(s) of pain, testing side).
The statistical analysis used to address the three aims with the alpha level is set at 0.05 for all statistical analyses: 1) three paired-t tests or Wilcoxon signed rank tests for the three cortical excitability variables (amplitudes of MEPs, ICF values, and SICI values), respectively, 2) two paired-t tests or Wilcoxon signed rank tests for the two neurosensory variables (PPT and CPM values), respectively, and 3) three 2 (group) x 2 (time) repeated measure ANOVAs to compare CS and non-CS group for the 3 cortical excitability variables, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two needles will be inserted on or near the most tender point of the low back. Two additional needles will be inserted on the opposite side at the level of the most tender point regardless of unilateral or bilateral low back pain (LBP). After piercing the skin, the needle will be directed toward the spinous process in a slight inferior-medial angle (approximately 20-30°). Once the needle is inserted, the treating investigator will use a ultrasound scanner to visualize the needle placement and to confirm that needle has reached the deeper layer of the lumbar multifidus (LM) muscle. Once the needle placement is confirmed, it will be pulled slightly in and out within the muscle and redirected in small angles for 10 seconds after insertion. The needles will stay (in situ) in the LM for approximately 10 minutes after the insertion and then will be withdrawn.
Procedure: Dry needling
Dry needling
Amplitude of motor evoked potential
Amplitude (uV) of motor evoked potential (MEP) will be obtained from the lumbar multifidus muscle during a submaximal contraction (i.e., 20% maximum voluntary isometric contractions) at a stimulus intensity of 130% of active motor threshold (AMT). AMT is defined as the transcranial magnetic stimulation intensity which yields a peak-to-peak amplitude of MEP larger than 200 μV in 5 out of 10 consecutive trials.
Time frame: Before and immediately after the intervention
Intracortical facilitation
Intracortical facilitation (%) is a ratio of the amplitude of the conditioned MEP relative to the amplitude of the corresponding test MEP. A subthreshold conditioning (second) TMS at the 90% AMT will be delivered 15 ms after a test (first) TMS at the 100% AMT.
Time frame: Before and immediately after the intervention
Short-interval intracortical inhibition
Short-interval intracortical inhibition (%) is a ratio of the amplitude of the conditioned MEP relative to the amplitude of the corresponding test MEP. A subthreshold conditioning (first) TMS at 70% AMT will be delivered 2 ms before a test TMS at a supra-threshold test TMS at 120% AMT.
Time frame: Before and immediately after the intervention
Pressure pain threshold
Pressure pain threshold (kPa) is a quantitative sensory test, used to measure deep muscular tissue sensitivity to mechanical pressure stimuli. The test determines the amount of pressure over the lumbar multifidus in which a steadily increasing non-painful pressure stimulus turns into a painful pressure sensation.
Time frame: Before and immediately after the intervention
Conditioned pain modulation
Conditioned pain modulation (CPM) is the perceived pain intensity for a test stimulus following application of a conditioning stimulus to a remote area of the body. A numerical pain rating scale (NPRS) (0-10) will be used to determine perceived pain intensity. The CPM score will be calculated by subtracting the NPRS score of the test stimulus in the presence of the conditioning stimulus, from the NPRS score of the test stimulus alone. Therefore, the CPM score will range from 0-10.
Time frame: Before and immediately after the intervention
Plan to share: Yes — All IPD that underlie results in a publication
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: When the summary data are published. Data obtained through this study may be provided to qualified researchers with academic interest in sickle cell anemia. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.
Access criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and execution of a Data Sharing Agreement (DSA).
Ran from Mar 2022 to primary completion in Apr 2024, 24 months.
Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 24 months is above that.
Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion May 2023 → Apr 2024 and completion May 2023 → Apr 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Texas Woman's University